Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Infection with hepatitis C virus (HCV) can cause liver scarring, or cirrhosis, and this
usually occurs more rapidly among people infected with both HCV and human immunodeficiency
virus (HIV). People infected with both HCV and HIV have poor response to the current HCV
treatments. This phase II pilot study evaluated whether adding a new HCV medication improves
response to the current standard HCV treatment with pegylated interferon and ribavirin in
people with both HCV and HIV.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)